Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound according to Formula (1):



(1)

wherein:

Y represents –C(O) – or a covalent bond;

R represents ~~a substituted~~ arylene, ~~a substituted~~ heteroarylene or a covalent bond;

Z represents $–CH_2–$, –NR3–, –O–, –C(O)NR3–, –NR3C(O)– or –CH=CH– when R is a substituted arylene or a substituted heteroarylene, and represents $–CH_2–$ or –CH=CH– when R is a covalent bond; R3 is hydrogen, C_{1-3} substituted alkyl, and $(CH_2)_{0-2}$ $–C_{3-6}$ substituted carbocycle;

R1 is selected from the group consisting of:

hydrogen, C_{1-3} substituted alkyl, C_{2-3} substituted alkenyl, C_{2-3} substituted alkynyl, and $(CH_2)_{0-2}$-C_{3-6} substituted carbocycle;

m is equal to 0 when Z = –NR3– or $–CH_2–$; or m is equal to 0 or 1 when Z = –O–, –C(O)NR3– or –NR3C(O)–; or m is is an integer between 0 and 6 when Z = –CH=CH–;

n is an integer equal to or greater than 2, appropriately chosen so that the number of atoms in the macrocyclic ring ranges from 13 to 16;

or a pharmaceutically acceptable salt~~, solvate, or physiologically functional derivative~~ thereof.

2. (Currently amended) [[A]] The compound according to claim 1, wherein R1 represents hydrogen; or a pharmaceutically acceptable salt thereof.

3. (Currently amended) [[A]] The compound according to claim 2, with the following absolute configuration:



or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof.

4. (Currently amended). [[A]] The compound according to claim 3 selected from the group consisting of:

N-{[(5R)-16-(Dimethylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(Cyclopropylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-Methyl-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-4-Oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-Methyl-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(2-Furanyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(Dimethylamino)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-4-Oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-14-Methyl-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-14-(Dimethylamino)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-14-(4-Morpholinyl)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide; and

N-{[(4R)-3,15-Dioxo-1,2-diazacyclopentadecan-4-yl]methyl}-N-hydroxyformamide; or a pharmaceutically acceptable salt thereof.

5. (Canceled).

6. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein Y represents –C(O) –.

7. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein Y represents a covalent bond.

8. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R represents a covalent bond.

9. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R represents heteroarylene.

10. (New) The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R represents 1,3,5-triazinyl; 1,3,5-triazinyl substituted with one dimethylamino, morpholinyl, or cyclopropylamino; 2-pyrimidinyl; or 2-pyrimidinyl substituted with one methyl, dimethylamino, or morpholinyl.

11. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein Z represents $-CH_2-$; and m is equal to 0.

12. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein n is 5, 6, 7, or 9.

13. (New) The compound according to claim 3 wherein
Y represents –C(O) – or a covalent bond:
R represents 1,3,5-triazinyl; 1,3,5-triazinyl substituted with one dimethylamino, morpholinyl, or cyclopropylamino; 2-pyrimidinyl; or 2-pyrimidinyl substituted with one methyl, dimethylamino, or morpholinyl; or a covalent bond;
Z represents $-CH_2-$;
m is equal to 0; and
n is 5, 6, 7; or 9; or a pharmaceutically acceptable salt thereof.

14. (New) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.